These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Epidemiology of invasive fungal disease by filamentous fungi in the period 2005 to 2015, in a university hospital in Santiago, Chile]. Valenzuela P; Legarraga P; Rabagliati R Rev Chilena Infectol; 2019 Dec; 36(6):732-741. PubMed ID: 33660752 [TBL] [Abstract][Full Text] [Related]
23. Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran. Sheikhbahaei S; Mohammadi A; Sherkat R; Naeini AE; Yaran M; Najafi S Endocr Metab Immune Disord Drug Targets; 2019; 19(3):302-307. PubMed ID: 30747087 [TBL] [Abstract][Full Text] [Related]
25. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276 [TBL] [Abstract][Full Text] [Related]
26. Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients. Khatri AM; Natori Y; Anderson A; Jabr R; Shah SA; Natori A; Chandhok NS; Komanduri K; Morris MI; Camargo JF; Raja M Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14162. PubMed ID: 37794708 [TBL] [Abstract][Full Text] [Related]
27. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies. Deng Q; Lv HR; Lin XM; Zhao MF; Geng L; Li YM Curr Med Res Opin; 2018 Jul; 34(7):1209-1216. PubMed ID: 28956459 [TBL] [Abstract][Full Text] [Related]
28. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Koehler P; Hamprecht A; Bader O; Bekeredjian-Ding I; Buchheidt D; Doelken G; Elias J; Haase G; Hahn-Ast C; Karthaus M; Kekulé A; Keller P; Kiehl M; Krause SW; Krämer C; Neumann S; Rohde H; La Rosée P; Ruhnke M; Schafhausen P; Schalk E; Schulz K; Schwartz S; Silling G; Staib P; Ullmann A; Vergoulidou M; Weber T; Cornely OA; Vehreschild MJ Int J Antimicrob Agents; 2017 Feb; 49(2):218-223. PubMed ID: 27989379 [TBL] [Abstract][Full Text] [Related]
29. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819 [TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies. Strand AM; Alexander BD; Sarpong E; Wong JR; Engemann A; Rizzieri D; Wu Y; Johnson MD Mycoses; 2022 Nov; 65(11):1050-1060. PubMed ID: 35816393 [TBL] [Abstract][Full Text] [Related]
31. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Bassetti M; Garnacho-Montero J; Calandra T; Kullberg B; Dimopoulos G; Azoulay E; Chakrabarti A; Kett D; Leon C; Ostrosky-Zeichner L; Sanguinetti M; Timsit JF; Richardson MD; Shorr A; Cornely OA Intensive Care Med; 2017 Sep; 43(9):1225-1238. PubMed ID: 28255613 [TBL] [Abstract][Full Text] [Related]
32. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. Rodriguez L; Bustamante B; Huaroto L; Agurto C; Illescas R; Ramirez R; Diaz A; Hidalgo J PLoS One; 2017; 12(4):e0175172. PubMed ID: 28419092 [TBL] [Abstract][Full Text] [Related]
33. The Changing Epidemiology of Invasive Fungal Infections. Enoch DA; Yang H; Aliyu SH; Micallef C Methods Mol Biol; 2017; 1508():17-65. PubMed ID: 27837497 [TBL] [Abstract][Full Text] [Related]
34. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Maertens J Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. Vannini M; Emery S; Lieutier-Colas F; Legueult K; Mondain V; Retur N; Gastaud L; Pomares C; Hasseine L J Mycol Med; 2022 Mar; 32(1):101210. PubMed ID: 34768155 [TBL] [Abstract][Full Text] [Related]
36. Challenges in management of invasive fungal infections in stem cell transplant. Walker J; Edwards WS; Hall NM; Pappas PG Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14175. PubMed ID: 37864814 [TBL] [Abstract][Full Text] [Related]
37. Cerebral and pulmonary aspergillosis, treatment and diagnostic challenges of mixed breakthrough invasive fungal infections: case report study. Amanati A; Lotfi M; Masoudi MS; Jafarian H; Ghasemi F; Bozorgi H; Badiee P BMC Infect Dis; 2020 Jul; 20(1):535. PubMed ID: 32703183 [TBL] [Abstract][Full Text] [Related]
38. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073 [TBL] [Abstract][Full Text] [Related]